Comparison of ketoconazole and griseofulvin for treatment of tinea capitis in childhood: A preliminary study

Robert R. Tanz*, Sheryl Stagl, Nancy B. Esterly

*Corresponding author for this work

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Treatment of children with tinea capitis currently consists of griseofulvin given orally for 1 to 3 months. Ketoconazole, a newer antifungal, is effective therapy for a variety of systemic mycoses. A randomized double-blind, placebo-controlled study was undertaken to compare ketoconazole and griseofulvin treatments of children with tinea capitis. Twenty-two patients were enrolled, and 14 completed the protocol. All patients had positive initial mycologic cultures. Seven evaluated patients received each drug. The treatment groups were comparable in terms of age, weight, sex, race, duration of infection, length of therapy, and initial disease severity. Adverse reactions occurred in three ketoconazole treated patients and in none receiving griseofulvin. After 6 weeks of therapy, ketoconazole-treated patients had improved as much as griseofulvin-treated patients and were as likely to have negative mycologic cultures. Ketoconazole shows promise as an alternative to griseofulvin for treating children with tinea capitis.

Original languageEnglish (US)
Pages (from-to)16-18
Number of pages3
JournalPediatric emergency care
Volume1
Issue number1
DOIs
StatePublished - Mar 1985

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Emergency Medicine

Fingerprint Dive into the research topics of 'Comparison of ketoconazole and griseofulvin for treatment of tinea capitis in childhood: A preliminary study'. Together they form a unique fingerprint.

  • Cite this